CRDF Stock Analysis: Buy, Sell, or Hold?
CRDF - Cardiff Oncology, Inc. Common Stock
$1.25
-0.05 (-3.85%)
▼
5d:
-11.97%
30d:
-30.17%
90d:
-29.78%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When CRDF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRDF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CRDF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CRDF is currently trading at $1.25, which is considered oversold relative to its 30-day fair value range of $1.37 to $1.80.
Technical Outlook: Technically, CRDF is in a strong downtrend. Immediate support is located at $1.16, while resistance sits at $1.64. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CRDF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.36 (+312.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRDF is in a strong downtrend. Immediate support is located at $1.16, while resistance sits at $1.64. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CRDF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.36 (+312.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.37 -
$1.80
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 312.1% below Wall St target ($5.36)
- CAUTION: 5-day price weakness (-12.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.37 -
$1.80
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$1.64
Current Trend
Strong Downtrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.60
Wall Street Target
$5.36
(+312.1%)
Revenue Growth (YoY)
-62.4%
Share & Embed Analysis
Last updated: June 23, 2026 4:38 PM ET
Data refreshes hourly during market hours. Next update: 5:38 PM
Data refreshes hourly during market hours. Next update: 5:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRDF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
